The period in brief – financial summary for the fourth quarter
- Net sales amounted to
SEK 0 million (SEK 0 ). - R&D expenses amounted to
SEK 17,1 million (SEK 11,6 million ). - Operating income amounted to
SEK -18,5 million (SEK -14,0 million ). - Income after financial items amounted to
SEK -18,5 million (SEK -14,0 million ). - Earnings per share, before and after dilution, amounted to
SEK -0.23 (SEK -0.22 ). - Cash flow from operating activities amounted to
SEK -12,5 million (SEK -9,8 million ).
Financial summary for the full year 2023
- Net sales amounted to
SEK 0 million (SEK 0 ). - R&D expenses amounted to
SEK 58,0 million (SEK 45,6 million ). - Operating income amounted to
SEK -65,0 million (SEK -51,9 million ). - Income after financial items amounted to
SEK -64,9 million (SEK -52,5 million ). - Earnings per share, before and after dilution, amounted to
SEK -0.81 (SEK -0.90 ). - Cash flow from operating activities amounted to
SEK -53,5 million (SEK -48,2 million ). - Equity amounted to
SEK 47,7 million (SEK 106,9 million ) orSEK 0.58 (SEK 1.34 ) per share. - The equity ratio was 73 percent (89 percent).
- Cash and cash equivalents amounted to
SEK 45,7 million (SEK 95,1 million ).
Significant events during the fourth quarter
Kancera reported that FIMEA has granted approval to conduct a phase I study of KAND145.Kancera reported that the phase I study of KAND145 has started.Kancera reported that additional sites have been added to the KANDOVA study and that in total five sites inSweden ,Norway andDenmark are now part of the study.Kancera submitted applications to the applicable regulatory authorities and ethical committees inSweden ,Norway andDenmark for modification of the KANDOVA study protocol, with specific regards to the patient inclusion criteria.Kancera reported positive top line results from the FRACTAL study.Kancera reported that it is exercising its option to obtain the rights to the results from the FRACTAL study from theUniversity of Newcastle .Kancera submitted applications to the WHO to obtain non-proprietary names for KAND567 and KAND145.
Important events after the end of the period
Kancera has reported detailed results from statistical analyses of the FRACTAL study results.Kancera has signed a license agreement with theUniversity of Newcastle concerning the exclusive global rights to the results from the FRACTAL study, including a submitted patent application.Kancera has received approval of the adjusted KANDOVA study protocol from all regulatory authorities and ethical committees.Kancera has completed the first part of the ongoing phase I study of KAND145.Kancera announces a planned rights issue.
About
For further information
Please refer the presentation of the 2023 Q4 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/
or contact:
CEO,
peter.selin@kancera.com or phone: +46 (0)8-5012 60 80
© Modular Finance, source